Display options
Cite
Ibrahim WN, Doolaanea AA, Bin Abdull Rasad MSB. Effect of shRNA Mediated Silencing of YB-1 Protein on the Expression of Matrix Collagenases in Malignant Melanoma Cell In Vitro. Cells. 2018;7(1)doi: 10.3390/cells7010007.
Ibrahim, W. N., Doolaanea, A. A., & Bin Abdull Rasad, M. S. B. (2018). Effect of shRNA Mediated Silencing of YB-1 Protein on the Expression of Matrix Collagenases in Malignant Melanoma Cell In Vitro. Cells, 7(1), . https://doi.org/10.3390/cells7010007
Ibrahim, Wisam Nabeel, et al. "Effect of shRNA Mediated Silencing of YB-1 Protein on the Expression of Matrix Collagenases in Malignant Melanoma Cell In Vitro." Cells vol. 7,1 (2018). doi: https://doi.org/10.3390/cells7010007
Ibrahim WN, Doolaanea AA, Bin Abdull Rasad MSB. Effect of shRNA Mediated Silencing of YB-1 Protein on the Expression of Matrix Collagenases in Malignant Melanoma Cell In Vitro. Cells. 2018 Jan 10;7(1). doi: 10.3390/cells7010007. PMID: 29320405; PMCID: PMC5789280.
Copy Download .nbib Format: NLM
Share it on

Cells. 2018 Jan 10;7(1). doi: 10.3390/cells7010007.

Effect of shRNA Mediated Silencing of YB-1 Protein on the Expression of Matrix Collagenases in Malignant Melanoma Cell In Vitro.

Cells

Wisam Nabeel Ibrahim, Abd Almonem Doolaanea, Mohammad Syaiful Bahari Bin Abdull Rasad

Affiliations

  1. Department of Basic Medical Sciences for Nursing, Faculty of Nursing, International Islamic University Malaysia, Kuantan Pahang 25200, Malaysia. [email protected].
  2. Department of Pharmaceutical Technology, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan Pahang 25200, Malaysia. [email protected].
  3. Department of BioMedical Sciences, Faculty of Allied Health Sciences, International Islamic University Malaysia, Kuantan Pahang 25200, Malaysia. [email protected].

PMID: 29320405 PMCID: PMC5789280 DOI: 10.3390/cells7010007

[No abstract available.]

Keywords: MMPs; YB-1; collagenases; malignant melanoma; shRNA

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Biochem J. 2013 Jan 1;449(1):11-23 - PubMed
  2. Mol Cancer. 2010 Jul 28;9:201 - PubMed
  3. Front Mol Biosci. 2015 May 13;2:19 - PubMed
  4. BMC Cancer. 2010 Oct 13;10:553 - PubMed
  5. Cancer Cell. 2009 May 5;15(5):357-9 - PubMed
  6. Br J Dermatol. 2004 Feb;150(2):179-85 - PubMed
  7. Int J Cancer. 2007 May 15;120(10):2110-8 - PubMed
  8. Biochim Biophys Acta. 2007 Sep-Oct;1769(9-10):525-31 - PubMed
  9. PLoS One. 2015 May 19;10(5):e0127224 - PubMed
  10. Biochemistry (Mosc). 2011 Dec;76(13):1402-33 - PubMed
  11. Nat Methods. 2012 Jul;9(7):671-5 - PubMed
  12. J Biol Chem. 2013 Jun 7;288(23 ):16282-94 - PubMed
  13. Cancer Cell. 2009 May 5;15(5):402-15 - PubMed
  14. Front Pharmacol. 2012 Jul 17;3:140 - PubMed
  15. Matrix Biol. 2015 May-Jul;44-46:191-9 - PubMed
  16. Endocr Rev. 2003 Aug;24(4):428-65 - PubMed
  17. Biochim Biophys Acta. 2010 Jan;1803(1):3-19 - PubMed
  18. Eur J Cell Biol. 2014 Jan-Feb;93(1-2):23-9 - PubMed
  19. Mol Cancer Ther. 2009 Dec;8(12 ):3276-84 - PubMed
  20. Matrix Biol. 2015 May-Jul;44-46:113-21 - PubMed
  21. Gynecol Oncol. 2009 Feb;112(2):319-24 - PubMed
  22. Rheumatol Int. 2011 Apr;31(4):543-7 - PubMed
  23. Cancer Res. 2017 Oct 15;77(20):5543-5553 - PubMed
  24. FEBS J. 2011 Jan;278(1):16-27 - PubMed
  25. J Vis Exp. 2014 Jun 01;(88):null - PubMed
  26. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009 Aug;26(4):400-5 - PubMed

Publication Types